[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"enteral-feeding-intolerance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:enteral-feeding-intolerance":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,49,70,103,127,148,174],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100600048","effect-of-semi-elemental-enteral-nutrition-on-gastrointestinal-tolerance-in-patients-with-traumatic-brain-injury-100600048",false,"NCT07092423","Effect of Semi-elemental Enteral Nutrition on Gastrointestinal Tolerance in Patients With Traumatic Brain Injury.","The Effect of Semi-elemental Enteral Nutrition on Gastrointestinal Tolerance in Patients With Traumatic Brain Injury: a Randomized Exploratory Study","SEMINAR","Inclusion Criteria:\n\n* Aged 18-75 years;\n* Clinically diagnosed with closed traumatic brain injury;\n* Glasgow Coma Scale (GCS) score ≤ 8;\n* Ability to initiate enteral nutrition within 48 hours post-injury;\n* Expected need for enteral nutrition support ≥3 days based on clinical assessment (Nutritional Risk Screening 2002 \\[NRS2002\\] score ≥3).\n\nExclusion Criteria:\n\n* GCS=3 with bilateral fixed and dilated pupils;\n* Hemodynamic instability or respiratory failure: mean arterial pressure \\\u003C70mmHg, PaO2\u002FFiO2\\\u003C150, PaCO2\\\u003C30 mmHg or \\>45 mmHg, or lactate \\>5 mmol\u002Fl;\n* Contraindications to both nasogastric and nasojejunal tube placement, or inability to complete tube placement within 48 hours of onset;\n* Contraindications to enteral nutrition therapy or semi-recumbent positioning;\n* Pre-existing intellectual disability or physical disability affecting outcome assessment;\n* Gastrointestinal abnormalities likely to affect gastrointestinal function, such as short bowel syndrome (defined as total small bowel length ≤122 cm), ulcerative colitis, Crohn's disease, or any form of ostomy;\n* Body mass index (BMI) \\\u003C18kg\u002Fm2;\n* Concomitant abdominal injury or extracranial injury with AIS score \\>3 in any region;\n* Presence of malignancy, severe cardiac insufficiency (ejection fraction \\\u003C50%), severe hepatic failure (Child-Pugh score ≥7), or severe renal failure (glomerular filtration rate ≤30 mL\u002Fmin or serum creatinine ≥4mg\u002FdL) at NICU admission;\n* Concurrent severe disease with expected survival ≤14 days;\n* Pregnancy, within 30 days postpartum, or breastfeeding;\n* Refusal of treatment or receipt of palliative care;\n* Patient or family declines informed consent;\n* Current participation in another interventional clinical trial.","ALL","18 Years","75 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","Study Objective This clinical trial primarily aims to investigate whether semi-elemental enteral nutrition (SEN) improves gastrointestinal tolerance in patients with severe traumatic brain injury (TBI) and to evaluate its impact on clinical outcomes. The safety profile of SEN will also be assessed.\n\nKey Research Questions Does SEN reduce the incidence of acute gastrointestinal injury (AGI) in severe TBI patients?\n\nStudy Design\n\nParticipants will be randomized 1:1 into either:\n\nIntervention group: Receives SEN initiated within 48 hours post-injury and continued for ≥7 days.\n\nControl group: Receives standard enteral nutrition over the same period.",[28,29,30],"Traumatic Brain Injury","Neurocritical Care","Enteral Feeding Intolerance",[28,32,33,34,29,35],"Enteral Nutrition","Gastrointestinal Intolerance","Semi-elemental Formula","Prognosis","RECRUITING","2026-04-26",{"date":39,"type":40},"2026-04-30","ACTUAL",{"date":42,"type":40},"2025-05-18",{"date":44,"type":22},"2027-05-31",{"name":46,"class":47},"Tang-Du Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":48},"100431629","effect-of-blenderized-enteral-tube-feeds-on-pediatric-upper-gastrointestinal-tract-physiology-100431629","NCT04900597","Effect of Blenderized Enteral Tube Feeds on Pediatric Upper Gastrointestinal Tract Physiology","Inclusion Criteria:\n\n* Age 1-21 years\n* G-tube\n* Able to tolerate bolus gastric feeds over 30 minutes\n* Use of conventional enteral formula\n* Undergoing impedance study for clinical purposes\n\nExclusion Criteria:\n\n* History of allergy or intolerance to any component of the test diets\n* History of Nissen fundoplication (participants with suspected or documented unwrapped fundoplication will be eligible for participation)\n* Current use of non-invasive pressure support (continuous or bi-level positive airway pressure)","1 Year",{"count":57,"type":22},45,[25],"Blenderized diets consist of a wide range of table foods such as fruits, vegetables, meat and legumes, pureed in a blender and administered via gastrostomy tube. In a recent study, the investigators reported that children receiving blenderized feeds via gastrostomy had fewer total admissions and respiratory admissions, total emergency room visits, and improved gastrointestinal symptom scores compared to those fed formula. The goal of this project is to understand how these diets affect gastroesophageal reflux burden.",[30],"2026-03-25",{"date":63,"type":40},"2026-03-30",{"date":65,"type":40},"2021-08-01",{"date":67,"type":22},"2026-12",{"name":69,"class":47},"Boston Children's Hospital",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":80,"conditions":81,"keywords":86,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100620017","undiluted-and-diluted-nutrition-100620017","NCT07352150","Undiluted and Diluted Nutrition","The Influence of Diluted and Undiluted Enteral Nutrition on Nutritional Tolerance in Critically Ill Patients After Gastrointestinal Surgery - a Randomized Controlled Trial","Inclusion Criteria:\n\nAdults, ≥18, Scheduled for major abdominal surgery requiring ICU admission Having access to the GI tract (gastric or jejunal) Planned to be fed enterally\n\nExclusion Criteria:\n\nPatients unable to give informed consent After emergency surgeries Without access to the GI tract Individuals with contraindications to EN, such as short bowel syndrome, uncompensated shock, acidosis (pH \\\u003C 7.1; lactate \\> 5 mmol\u002Fl), bleeding from the upper GI tract, obstruction, intestinal ischemia, abdominal compartment syndrome Patients with symptomatic gastro-esophageal reflux Expected ICU stay \\\u003C 3 days Pregnancy and lactation",{"count":78,"type":22},80,[25],"Adult patients after elective major abdominal surgeries who are planned to be admitted to the Intensive Care Unit (ICU) can be included in the trial. Each patient will be fed via the gastrointestinal tract. Half of the patients will receive enteral nutrition (EN) with additional fluids, and the rest will receive undiluted EN. The primary aim of this study is to assess feeding intolerance in both patient groups.",[82,83,30,84,85],"Critical Illness","Gastro Intestinal Surgery","Gastro-Intestinal Disorder","Quality of Lifte",[87,88,89,90,91],"Zonulin","Intestinal fatty-acid binding protein (I-FABP)","Ketones","enteral feeding","GNAK","NOT_YET_RECRUITING","2026-01-11",{"date":95,"type":40},"2026-01-20",{"date":97,"type":22},"2026-02-02",{"date":99,"type":22},"2027-09-30",{"name":101,"class":47},"John Paul II Catholic University of Lublin",2,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":23,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":48},"100616997","bedside-observation-by-clinical-ultrasound-for-stomach-expansion-100616997","NCT07312890","Bedside Observation by Clinical Ultrasound for Stomach Expansion","BOCUSE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Predicted mechanical ventilation ≥ 48 hours\n* Initiation of enteral nutrition via nasogastric or orogastric tube for ≥ 48 hours\n* Free and informed consent obtained from the patient's relative or legal representative, or inclusion in an emergency situation\n\nExclusion Criteria:\n\n* History of major gastric surgery (bypass, total gastrectomy, biliopancreatic diversion)\n* Enteral nutrition via nasogastric or orogastric tube \\> 96 hours\n* Initiation of enteral nutrition before intubation\n* Feeding via gastrostomy, jejunostomy, or jejunal tube\n* Pregnancy\n* Prognosis considered terminal\n* No ultrasound window available\n* Legally protected adults (under curatorship, guardianship, or judicial protection)\n* No social security coverage\n* Patient under State Medical Aid (AME)",{"count":111,"type":22},150,[25],"The objective of the BOCUSE study is to demonstrate a relationship between an early ultrasound measurement of the gastric antral area and the subsequent occurrence of poor gastric tolerance.",[30],[116,117],"Enteral feeding intolerance","Gastric antral area","2025-12-17",{"date":120,"type":40},"2025-12-31",{"date":122,"type":40},"2025-10-25",{"date":124,"type":22},"2027-01-25",{"name":126,"class":47},"Centre Hospitalier Saint Joseph Saint Luc de Lyon",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":48},"100579603","phase-3-a-comparative-evaluation-of-mosapride-versus-metoclopramide-for-enteral-feeding-intolerance-in-critically-ill-patients-100579603","NCT06826443","A Comparative Evaluation of Mosapride Versus Metoclopramide for Enteral Feeding Intolerance in Critically Ill Patients","Inclusion Criteria:\n\n* Patients aging between 18 and 60 years (of both sexes)\n* Patients admitted to the ICU and are expected to stay in the ICU for not less than 7 days\n* Patients prescribed enteral feeding.\n\nExclusion Criteria:\n\nThe following patients are\n\n* Age less than 18 years or more than 60 years.\n* Patients who had previous upper gastrointestinal tract surgery, obstruction, hemorrhage or history of GI disease.\n* Patients who are clinically significant hepatic dysfunction. (\\>3 times above the upper end of normal range of bilirubin, γ-glutamyl transferase, aspartate transaminase, or lactate dehydrogenase)\n* Patients who are on regular use of H2 blockers, prokinetic, proton pump inhibitor or anticholinergic agents for previous 4 weeks.\n* Patients with arrhythmia or atrioventricular blocks.\n* Patients with any condition or comorbid disease that might interfere with gastric emptying such as diabetes.\n* Patients with head injuries.","60 Years",{"count":21,"type":22},[136],"PHASE3","Caring for critically ill patients in an intensive care unit (ICU) is considered a standard of care. According to the Society of Critical Care Medicine (SCCM), as a function of the complex nature of the care provided in the ICU, the ideal method to provide support to the critically ill involves the participation of a multi-professional staff.\n\nProvision of nutrition support to the critically ill is now established as an essential part of patient care where aiming toward 100% of the predicted target may have resulted in reduced mortality and increased ventilator-free days in those who are premorbid malnourished. Despite these reported benefits, clinicians continue to deliver little more than half of the enteral nutrition (EN) they plan to provide, due to gastric motility disorders, patient intolerance and clinical interruptions. Also despite the availability of numerous clinical practice guidelines (CPGs) focused on feeding critically ill patients, observational studies have consistently demonstrated persistent and significant gaps between guideline recommendations and actual nutrition practice. Consequently, underfeeding is prevalent in the intensive care unit (ICU), with patients on average receiving only 60 % of the calories that are prescribed. Moreover, Among the barriers to adequate nutritional supply in the ICU which contributes to nutritional status deterioration, gastrointestinal disorders causing enteral feed intolerance are the most important and the most often mentioned in the literature. when gastric emptying was measured in critically ill patients, 46 % of them had evidence of delayed gastric emptying. Untreated slow gastric emptying has a plethora of clinical consequences such as vomiting, aspiration of gastric contents, pneumonia, and contributes significantly to the frequent interruptions and cessation of EN in the ICU, which results in inadequate nutritional delivery. Studies have shown an association between feeding intolerance, prolonged intensive care unit (ICU) stay, and increased risk of death.\n\nGuidelines for the provision and assessment of nutrition support therapy in the adult critically ill patients has demonstrated the importance of the use of prokinetic drugs to improve tolerance to gastric feeding in critically ill patients and achieve earlier discharge.\n\nProkinetic drugs act by promoting gastric motility, increase gastric emptying, prevent the retention and reflux of gastric contents and thus provide symptomatic relief.\n\nMost of the prokinetic drugs are efficacious with prokinetic activity but the matter of major concern is their side effect profile. The most commonly used agent is metoclopramide. Although it is the most commonly used prokinetic to treat delayed gastric emptying and facilitate early enteral feeding, adverse complications limit its use including tachyphylaxis, tardive dyskinesia on long term use and QT prolongation predisposing to cardiac arrhythmias. Several drug targets have been identified to develop new promotility agents and several new medications are under investigation to overcome the side effects caused by most of the prokinetics .\n\nMosapride is another available prokinetic agent that enhances gastric motility through serotonin receptor agonism; resulting in prokinetic effects. It accelerates gastric emptying, improves gastric tension and sensitivity, and has anti-emetic action.\n\nThe aim of the current study is to compare the effectiveness as well as the safety of Mosapride against metoclopramide as the first line treatment for feeding intolerance in critically ill patients.",[30],"2025-02-13",{"date":141,"type":40},"2025-02-17",{"date":143,"type":22},"2025-02",{"date":145,"type":22},"2025-05",{"name":147,"class":47},"Ain Shams University",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":75,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":23,"phases":157,"briefSummary":158,"conditions":159,"keywords":162,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":173},"100555803","diluted-and-undiluted-enteral-nutrition-100555803","NCT06516835","Diluted and Undiluted Enteral Nutrition","Inclusion Criteria:\n\n* Scheduled for major abdominal surgery requiring ICU admission\n* Having access to the GI tract (gastric or jejunal)\n* Planned to be fed enterally\n\nExclusion Criteria:\n\n* Patients unable to give informed consent\n* After emergency surgeries\n* Without access to the GI tract\n* Individuals with contraindications to EN, such as short bowel syndrome, uncompensated shock, acidosis (pH \\\u003C 7.1; lactate \\> 5 mmol\u002Fl), bleeding from the upper GI tract, obstruction, intestinal ischemia, abdominal compartment syndrome\n* Patients with symptomatic gastro-esophageal reflux\n* Expected ICU stay \\\u003C 3 days\n* Pregnancy and lactation","80 Years",{"count":156,"type":22},60,[25],"Adult patients after elective major abdominal surgeries who are planned to be admitted to the Intensive Care Unit (ICU) can be included in the trial.\n\nEach patient will be fed via the gastrointestinal tract. Half of the patients will receive enteral nutrition (EN) with additional fluids, and the rest will receive undiluted EN.\n\nThe primary aim of this study is feeding intolerance assessment in both groups of patients.",[82,160,30,84,161],"Surgery","Quality of Life",[87,88,89,163],"Microbiome","2024-07-24",{"date":166,"type":40},"2024-07-26",{"date":168,"type":22},"2025-01-02",{"date":170,"type":22},"2027-04-30",{"name":172,"class":47},"Medical University of Lublin",5,{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":183,"phases":4,"briefSummary":184,"conditions":185,"keywords":190,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":196,"completionDateStruct":197,"leadSponsor":199,"locationsCount":48},"100555598","gastrointestinal-dysfunction-in-aortic-surgery-patients-100555598","NCT06514170","Gastrointestinal Dysfunction in Aortic Surgery Patients","Assessment of Gastrointestinal Dysfunction Through GIDS Scale and Intestinal Damage Biomarkers in Critically Ill Patients Undergoing Aortic Surgery and Its Association With Clinical Outcomes.","Inclusion Criteria:\n\n* 18 years of age or older.\n* Patients after surgical interventions (elective or urgency) on the aorta with cardiopulmonary bypass.\n* Invasive mechanical ventilation expected to be required more than 48 hours.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients under mechanical ventilation with pre-existing gastrointestinal issues.\n* Diagnosis of adult congenital heart disease.\n* Ongoing pregnancy or lactation period.\n* Simultaneous participation in another clinical study involving experimental therapy.\n* Presence of chronic intestinal disease.\n* Previous gastrointestinal conditions detected during nutritional screening.",{"count":182,"type":22},114,"OBSERVATIONAL","The goal of this observational study is to determine the association of gastrointestinal dysfunction through the Gastrointestinal Dysfunction Scale (GIDS) tool and serum concentrations of citrulline and Intestinal fatty-acid binding protein (I-FABP) with primary \\[calories received, protein received, parenteral nutrition requirement and 28-day mortality in the intensive care unit (ICU)\\] and secondary (development of pneumonia, surgical and cardiovascular complications in the ICU, length of hospital and ICU stay, duration of mechanical ventilation) clinical outcomes in critically ill patients undergoing aortic surgery.",[186,187,188,30,189],"Aortic Aneurysm","Gastrointestinal Dysfunction","Aortic Diseases","Surgical Complication",[191,192,193],"Gastrointestinal dysfunction","Aortic diseases","Aorta surgery","2024-07-23",{"date":164,"type":40},{"date":194,"type":40},{"date":198,"type":22},"2026-06",{"name":200,"class":47},"Instituto Nacional de Cardiologia Ignacio Chavez"]